PSYCHEMEDICS CORP
PMDIOTCHealthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $19.7M | $22.1M | $25.2M | $24.9M | $21.4M | $37.7M |
| Operating income | −$1.9M | −$2.9M | −$1.1M | $209,000 | −$6.1M | $3.0M |
| Net income | −$1.9M | −$4.2M | −$1.1M | −$665,000 | −$3.9M | $1.5M |
| Total assets | $8.3M | $12.3M | $18.7M | $21.6M | $24.0M | $27.5M |
| Total liabilities | $3.2M | $5.7M | $8.0M | $9.3M | $11.5M | $10.7M |
| Equity | $5.1M | $6.7M | $10.8M | $12.2M | $12.5M | $16.8M |
| EPS (diluted) | $-0.32 | $-0.72 | $-0.19 | $-0.12 | $-0.70 | $0.28 |
| Shares out. | 5.8M | 5.7M | 5.6M | 5.5M | 5.5M | 5.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −9.6%
- Net margin
- −9.5%
- Return on equity
- −36.3%
- Return on assets
- −22.4%
- Return on capital (ROCE)
- −33.8%
- Liabilities / assets
- 38.3%
- Debt / equity
- 0.62×
- Book value / share
- $0.88
- Revenue growth (YoY)
- −10.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -5.39distress
- Accruals / assets
- −33.5%clean
- Beneish M-Score
- -4.33normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 16, 2011
- NT 10-Qmissed a reporting deadline ↗May 15, 2009
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Powell Anderson Capital Partners Llc10% owner | Dec 13, 2024 | Buy | 80,000 | $1.88 |
| Powell Anderson Capital Partners Llc10% owner | Dec 10, 2024 | Buy | 7,473 | $2.59 |
| Kamin PeterDirector | Dec 10, 2024 | Sell | 320,708 | $2.35 |
| Kamin PeterDirector | Dec 3, 2024 | Buy | 1.4M | $2.35 |
| Weisenhoff Michael | Aug 17, 2023 | Grant | 4,000 | $0.00 |
| Doucot Charles MOfficer — Executive Vice President | Aug 17, 2023 | Sell | 12,700 | $4.66 |
| Reynolds AndrewDirector | Aug 17, 2023 | Grant | 14,000 | $0.00 |
| Davis Robyn CDirector | Aug 17, 2023 | Grant | 14,000 | $0.00 |
| Kamin PeterDirector | Aug 17, 2023 | Grant | 14,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2,246 | 1.0 | +42.4% |
| Apr 30, 2026 | 1,577 | 1.0 | +294.3% |
| Apr 15, 2026 | 400 | 1.0 | -22.3% |
| Mar 31, 2026 | 515 | 1.0 | +329.2% |
| Mar 13, 2026 | 120 | 1.0 | -92.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventDec 10, 2024
- Delisting / listing-standard notice · Other material eventDec 3, 2024
- Shareholder voteNov 25, 2024
- Results of operationsNov 12, 2024
- Results of operationsAug 13, 2024
- Entered a material agreement · Unregistered equity sale · Other material eventAug 12, 2024
- Changed auditorJun 12, 2024
- Terminated a material agreementJun 3, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-KFORM 10-KMar 24, 2025
- S-8 POSFORM S-8 POSMar 19, 2025
- S-8 POSFORM S-8 POSMar 19, 2025
- S-8 POSFORM S-8 POSMar 19, 2025
- S-8 POSFORM S-8 POSMar 19, 2025
- S-8 POSFORM S-8 POSMar 19, 2025
- S-8 POSFORM S-8 POSMar 19, 2025
- S-8 POSFORM S-8 POSMar 19, 2025
- 15-12GFORM 15-12GJan 2, 2025
- 4OWNERSHIP DOCUMENTDec 17, 2024
- 25FORM 25Dec 13, 2024
- 4OWNERSHIP DOCUMENTDec 12, 2024
- SC 13D/ADec 12, 2024
- 4PRIMARY DOCUMENTDec 12, 2024
- SC 13E3/AFORM SC 13E3/ADec 10, 2024